In this regard, multiple studies have validated the superior efficacy of positron emission tomography (PET) targeting the prostate-specific membrane antigen (PSMA), an transmembrane protein overexpressed on prostate cancer cells, over conventional cross-sectional imaging modalities [2,3,4,5]. This evidence concerns the gene FOLH1 and Familial prostate cancer.